HIGHLIGHTS
- who: Jingjing Deng et al. from the University of Arizona, United States have published the paper: Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy, in the Journal: (JOURNAL)
- future: More studies are needed to carefully evaluate the benefit of antiBCMA CAR-T therapy in PCL patients.
SUMMARY
The Food and Drug Administration has approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) and ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.), which are both B-cell maturation antigen (BCMA)-directed genetically modified autologous CAR-T_cell . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.